---
schema_version: "secwatch.filing_event.v1"
accession: "0001649094-25-000027"
form_type: "8-K"
ticker: "PCVX"
cik: "0001649094"
company_name: "Vaxcyte, Inc."
filed_at: "2025-02-25T23:59:59+00:00"
generated_at: "2026-05-26T04:47:49.037030+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Vaxcyte reports Q4 2024 net loss of $137.1M; cash $3.13B; VAX-31 Phase 3 on track for mid-2025

## Summary
- Net loss Q4 2024: $137.1M; full year 2024: $463.9M vs $402.3M in 2023.
- Cash, cash equivalents and investments: $3.13B at Dec 31, 2024, up from $1.24B a year ago.
- R&D expenses $133.6M in Q4; $476.6M for full year on increased PCV program activities.
- VAX-31 adult Phase 3 pivotal study expected to start by mid-2025 with topline data in 2026.
- VAX-24 infant Phase 2 primary immunization topline data expected by end of Q1 2025.

## SEC filing metadata
- accession: 0001649094-25-000027
- form_type: 8-K
- ticker: PCVX
- cik: 0001649094
- company_name: Vaxcyte, Inc.
- filed_at: 2025-02-25T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1649094/000164909425000027/0001649094-25-000027-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1649094/000164909425000027/pcvx-20250225.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001649094-25-000027
- JSON: https://secwatch.observer/filing/0001649094-25-000027.json
- Plain text: https://secwatch.observer/filing/0001649094-25-000027.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.